Arch Therapeutics (OTCMKTS:ARTH – Get Free Report) and KORU Medical Systems (NASDAQ:KRMD – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.
Analyst Recommendations
This is a summary of recent recommendations for Arch Therapeutics and KORU Medical Systems, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arch Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| KORU Medical Systems | 1 | 0 | 4 | 0 | 2.60 |
KORU Medical Systems has a consensus price target of $7.00, indicating a potential upside of 105.82%. Given KORU Medical Systems’ stronger consensus rating and higher possible upside, analysts clearly believe KORU Medical Systems is more favorable than Arch Therapeutics.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arch Therapeutics | $80,000.00 | 9.53 | -$6.98 million | ($2.34) | -0.07 |
| KORU Medical Systems | $41.13 million | 3.80 | -$2.64 million | ($0.04) | -85.02 |
KORU Medical Systems has higher revenue and earnings than Arch Therapeutics. KORU Medical Systems is trading at a lower price-to-earnings ratio than Arch Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Arch Therapeutics and KORU Medical Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arch Therapeutics | -8,257.70% | N/A | -730.22% |
| KORU Medical Systems | -4.03% | -10.63% | -6.51% |
Insider and Institutional Ownership
6.9% of Arch Therapeutics shares are owned by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are owned by institutional investors. 4.5% of Arch Therapeutics shares are owned by company insiders. Comparatively, 18.5% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
Arch Therapeutics has a beta of 4.02, suggesting that its stock price is 302% more volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.
Summary
KORU Medical Systems beats Arch Therapeutics on 10 of the 14 factors compared between the two stocks.
About Arch Therapeutics
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
